Notícias e Atividades da Ideaya Biosciences

Ideaya Biosciences é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Ideaya Biosciences é uma empresa listada sob o símbolo IDYA (US).

Veja o organograma con seus 28 executivos principais

Biografias mais buscadas da Ideaya Biosciences

• Yujiro Hata, Chief Executive Officer and Director
• Susan Kelley, Director
• Garret Hampton, Director

Recentes movimentos de executivos em Ideaya Biosciences

• Theodora Ross, ingressou na Companhia como Chief Development Officer  (Notícia publicada em 23 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Ideaya Biosciences.

Ideaya Biosciences possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Ideaya Biosciences

• Investor Relations | IDEAYA Biosciences - News ReleasesBack ButtonSearch IconFilter Icon
• IDEAYA to Participate in Upcoming November 2020 Investor Relations Events - IDEAYA Biosciences
• IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform - IDEAYA Biosciences
• IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations - IDEAYA Biosciences
• IDEAYA to Participate in Upcoming September 2020 Investor Relations Events - IDEAYA Biosciences
• IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update - IDEAYA Biosciences
• IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment - IDEAYA Biosciences
• IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial - IDEAYA Biosciences
• IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020 - IDEAYA Biosciences
• IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor - IDEAYA Biosciences
• View more press releases Close

Redes sociais sobre Ideaya Biosciences

• Ideaya Biosciences na Wikipedia, Google News e Yahoo Finance
• Ideaya Biosciences na LinkedIn, X (Twitter) e YouTube